SCHEMBL17418027

SCHEMBL17418027

C[C@@H](Cl)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.47
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
TP53 P04637 2/20 0.36
CYP3A4 P08684 1/20 0.36
ADRB2 P07550 1/20 0.35
IDO1 P14902 1/20 0.34
TDO2 P48775 1/20 0.34
RAPGEF4 Q8WZA2 1/20 0.33
GRN P28799 1/20 0.33
SORT1 Q99523 1/20 0.33
CYP1A2 P05177 1/20 0.32
POLB P06746 1/20 0.32
CYP2C19 P33261 1/20 0.32
ALDH1A1 P00352 2/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
APP P05067 2/20 0.31
MAPK1 P28482 1/20 0.31
HIF1A Q16665 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16099813 1.00 TSHR (0.47) TSHRGABRA1GABRB1TP53CYP3A4
SCHEMBL16099814 1.00 TSHR (0.47) TSHRGABRA1GABRB1TP53CYP3A4
SCHEMBL20868259 0.83 RAPGEF4 (0.39) TSHRGABRA1GABRB1RAPGEF4APP
SCHEMBL30512228 0.83 RAPGEF4 (0.39) TSHRGABRA1GABRB1RAPGEF4APP
1,3,5-Trichlorobenzene SCHEMBL28732101 0.81 TSHR (0.61) TSHRGABRA1GABRB1TP53CYP3A4
SCHEMBL27906066 0.81 ALDH1A1 (0.36) TSHRALDH1A1
SCHEMBL9027036 0.80 TSHR (0.44) TSHRGABRA1GABRB1TP53CYP3A4
SCHEMBL422198 0.79 TSHR (0.50) TSHRGABRA1GABRB1TP53CYP3A4
SCHEMBL674090 0.79 TSHR (0.50) TSHRGABRA1GABRB1TP53CYP3A4
Ammonia Solution, Strong SCHEMBL5676040 0.77 TSHR (0.47) TSHRGABRA1GABRB1TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9550775-B2 Substituted triazolopyridines and methods of use thereof GENENTECH, INC. (US) 2017-01-24 US disclosed
US-20160009710-A1 SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF XENON PHARMACEUTICALS INC. (CA) 2016-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009710-A1 SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF P2RX3, P2RX1, P2RX4 TSHR 354/4885GABRA1 3387/4885GABRB1 3557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.